Abstract
Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung destruction. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current focus of treatment for AAT deficiency. While augmentation is a cornerstone of therapy for individuals with AAT deficiency, practitioners must also maximize standard treatment for obstructive lung disease like chronic obstructive pulmonary disease (COPD) to provide improved quality of life in patients suffering from AAT deficiency. Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics are essential therapies for the management of AAT deficiency.
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy
Volume: 9 Issue: 4
Author(s): Amit Mahajan and D. Kyle Hogarth
Affiliation:
Keywords: Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment. augmentation therapy, smoking cessation, pulmonary rehabilitation.
Abstract: Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung destruction. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current focus of treatment for AAT deficiency. While augmentation is a cornerstone of therapy for individuals with AAT deficiency, practitioners must also maximize standard treatment for obstructive lung disease like chronic obstructive pulmonary disease (COPD) to provide improved quality of life in patients suffering from AAT deficiency. Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics are essential therapies for the management of AAT deficiency.
Export Options
About this article
Cite this article as:
Mahajan Amit and Kyle Hogarth D., Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (4) . https://dx.doi.org/10.2174/1871523011009040330
DOI https://dx.doi.org/10.2174/1871523011009040330 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design The Immunologic Barriers to Replacing Damaged Organs
Current Immunology Reviews (Discontinued) Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Henoch Schonlein Purpura in Childhood
Current Pediatric Reviews Persistent Pulmonary Hypertension of the Newborn: Therapeutical Approach
Mini-Reviews in Medicinal Chemistry Self Managing Heart Failure in Remote Australia - Translating Concepts into Clinical Practice
Current Cardiology Reviews NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Quorum-Sensing Inhibitors and Biofilms
Anti-Infective Agents in Medicinal Chemistry Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders
Current Molecular Medicine Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design